New panel formed to discuss regulation of pharmaceuticals
Pharmaceutical manufacturers have the opportunity to put forward issues on the regulation of pharmaceuticals in a new discussion forum designed to help the UK's Department of Health's Ministerial Industry Strategy Group (MISG) develop a long-term plan for medicines.
Pharmaceutical manufacturers have the opportunity to put forward issues on the regulation of pharmaceuticals in a new discussion forum designed to help the UK's Department of Health's Ministerial Industry Strategy Group (MISG) develop a long-term plan for medicines.
In February 2006, the MISG agreed to establish a Panel and a Forum, jointly sponsored by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Association of the British Pharmaceutical Industry (ABPI), to discuss future challenges in the regulation of pharmaceuticals.
The MISG's aim is to secure the provision of safe and effective medicines for patients, whilst maintaining and strengthening the UK pharmaceuticals industry within Europe, and to advance healthcare innovation with the UK's National Health Service.
The first meeting of the Forum is to be held early in 2007 and compnanies are now invited to submit proposals for topics.
The Forum will meet twice a year, to discuss scientific developments and topics that may have a significant future impact upon the regulation of pharmaceutical development or registration, in order to ensure that the relevant UK regulatory authorities are aware and ready to meet predictable new directions and challenges.
An advisory panel made up of industry, regulators, representatives of the clinical academic community and a lay representative, is being established to identify suitable topics for the Forum.